Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lonza, Index Ventures Ink Exclusive Biologics Production Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Lonza, Index Ventures Ink Exclusive Biologics Production Pact

To manufacture biologics for Index portfolio companies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lonza and Index Ventures, a venture capital investment firm, have entered an exclusive agreement for process development and cGMP production of all biologics for Index Ventures’ portfolio of companies. The companies may add projects during the five-year agreement, as Index makes future investments.
 
“This agreement shows that Lonza’s value to a company’s product development pipeline is being recognized more widely by investors in biotech companies,” said Dr. Stephan Kutzer, chief operating officer of Lonza Pharma & Biotech. “This multi-product agreement demonstrates Lonza’s ability to offer world-class expression platforms in combination with secure manufacturing capabilities for the complete product lifecycle.” 
 
Kevin Johnson, partner at Index Ventures, said, “Lonza has manufactured the majority of the antibody products I’ve worked on in the last 20 years and proved to be an excellent partner. I’m pleased that we’re now able to extend that expertise to our asset-centric portfolio companies, enabling them to benefit as though they were much larger organizations.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics